Moravejolahkami Amir Reza, Hojjati Kermani Mohammad Ali, Balouch Zehi Zakiyeh, Mirenayat Seyed Mohammad Sadegh, Mansourian Marjan
Department of Clinical Nutrition, School of Nutrition & Food Science, Isfahan University of Medical Sciences, P.O. Box 81746-73461, Hezar-Jerib Ave, Isfahan, Iran.
Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
J Diabetes Metab Disord. 2021 Feb 23;20(1):893-904. doi: 10.1007/s40200-021-00765-8. eCollection 2021 Jun.
Recent trials have demonstrated the possible improvements in lipid profile & anthropometric indices after probiotics supplementation. We aimed to reanalyze the related literature to explore the efficacy of probiotics in Diabetic Nephropathy (DN) patients.
PubMed, Embase, Web of science, google scholar, Scopus, and Cochrane Library databases were systematically searched to find the related data on diabetic nephropathy population. All Randomized controlled trials (RCTs) that investigated the effect of probiotics on serum lipid markers (High-Density Lipoprotein [HDL], Triglyceride, Total Cholesterol, TC-to-HDL ratio, Low-Density Lipoprotein, Very Low-Density Lipoprotein) and anthropometric indices (Body Weight, Body Mass Index, waist-to-hip ratio) were included (PROSPERO No.CRD42020186189). Meta-analysis was performed using the random-effect model.
Of 156 studies, seven were eligible for inclusion. Lipid biomarkers had a marginal reduction (except for HDL; WMD = 2.59 mg/dl; 95% CI = -0.28, 5.47; ); whereas anthropometric indices increased in a non-significant manner.
There is limited evidence to support the efficacy of probiotics for the modulation of lipid profile and anthropometric indices in DN patients.
Probiotics did not beneficial effect on lipid profile & anthropometric markers in Diabetic Nephropathy; anyway, more trials should be conducted.
The online version contains supplementary material available at 10.1007/s40200-021-00765-8.
近期试验表明补充益生菌后血脂谱和人体测量指标可能得到改善。我们旨在重新分析相关文献，以探讨益生菌对糖尿病肾病（DN）患者的疗效。
系统检索PubMed、Embase、Web of science、谷歌学术、Scopus和Cochrane图书馆数据库，以查找糖尿病肾病人群的相关数据。纳入所有研究益生菌对血清脂质标志物（高密度脂蛋白[HDL]、甘油三酯、总胆固醇、TC与HDL比值、低密度脂蛋白、极低密度脂蛋白）和人体测量指标（体重、体重指数、腰臀比）影响的随机对照试验（RCT）（国际前瞻性系统评价注册库编号：CRD42020186189）。使用随机效应模型进行荟萃分析。
在156项研究中，有7项符合纳入标准。脂质生物标志物有轻微降低（HDL除外；加权均数差[WMD]=2.59mg/dl；95%置信区间[CI]=-0.28，5.47）；而人体测量指标呈非显著性增加。
支持益生菌调节DN患者血脂谱和人体测量指标疗效的证据有限。
益生菌对糖尿病肾病患者的血脂谱和人体测量指标无有益影响；无论如何，应开展更多试验。
在线版本包含可在10.1007/s40200-021-00765-8获取的补充材料。
